

**Clonal hematopoiesis of indeterminate potential and diabetic kidney
disease: a nested case-control study**

Supplementary Material

Supplementary tables and figures

Table of content:


Supplementary Table S1: Inclusion and exclusion criteria	2
Supplementary Figure S1: Selection of the study population	3
Supplementary Table S2: Components of the composite outcome	4
Supplementary Table S3: Next generation sequencing panel	5
Supplementary Table S4: Multiplex cytokine assay	7
Supplementary Table S5: Principal component analysis	8
Supplementary Table S6: List of identified CHIP-associated variants	9

Supplementary Table S1: Inclusion and exclusion criteria

Inclusion criteria	Exclusion criteria
<ul style="list-style-type: none">– Incident or prevalent T2DM (inclusion criterion of PROVALID)– Age > 18 years (inclusion criterion of PROVALID)– Available baseline peripheral blood samples– Complete information on important baseline covariates* required for the adjusted statistical analysis	<ul style="list-style-type: none">– Active malignancy (exclusion criterion of PROVALID)– Any history of malignancy at baseline– Other (non-diabetic) kidney disease at baseline according to the judgement of the recruiting physician– Baseline eGFR < 20 ml/min/1.73m²– Short follow-up (i.e. lost to follow-up before follow-up 2). However, individuals who died or initiated kidney replacement therapy before follow-up 2 were not excluded to avoid selection bias.

*BL covariates: date of visit, country, gender, age, year of T2DM diagnosis, smoking, systolic and diastolic blood pressure, HbA1C, serum cholesterol (total), serum cholesterol (LDL), serum triglycerides, serum cholesterol (HDL), hemoglobin, body weight, height, eGFR, albuminuria, C-reactive protein (CRP), history of heart failure stage III or IV, history of coronary artery disease (any angina, myocardial infarction, coronary intervention), history of peripheral artery disease (claudicatio, amputation, etc.), history of cerebrovascular disease (stroke, transient ischemic attack, prolonged reversible ischemic neurological deficit), history of diabetic retinopathy. T2DM, type 2 diabetes mellitus; eGFR, estimated glomerular filtration rate.

Supplementary Figure S1: Selection of the study population



*BL covariates: date of visit, country, gender, age, year of T2DM diagnosis, smoking, systolic and diastolic blood pressure, HbA1C, serum cholesterol (total), serum cholesterol (LDL), serum triglycerides, serum cholesterol (HDL), hemoglobin, body weight, height, eGFR, albuminuria, C-reactive protein (CRP), history of heart failure stage III or IV, history of coronary artery disease (any angina, myocardial infarction, coronary intervention), history of peripheral artery disease (claudicatio, amputation, etc.), history of cerebrovascular disease (stroke, transient ischemic attack, prolonged reversible ischemic neurological deficit), history of diabetic retinopathy T2DM, type 2 diabetes mellitus; eGFR, estimated glomerular filtration rate.

Supplementary Table S2: Components of the composite endpoint

Component	Number
– Decline in eGFR of $\geq 40\%$ from baseline to < 60 ml/min/1,73m ²	25*
– Progression to macroalbuminuria including a 30% increase in the mean UACR from baseline	32*
– Initiation of kidney replacement therapy	7
– Death from kidney failure	2

* both events occurred simultaneously in two patients. UACR, urine albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate.

Supplementary Table S3: Next generation sequencing panel

Genes	Chromosomes	Exons	NM-Nr.
<i>ABL1</i>	9	4-6	NM_007313.3
<i>ASXL1</i>	20	13	NM_015338.5
<i>ATRX</i>	X	8, 10-11,17-31	NM_000489.5
<i>BCOR</i>	X	2-15	NM_001123385.1
<i>BCORL1</i>	X	1-12	NM_021946.4
<i>BRAF</i>	7	15	NM_004333
<i>CBL</i>	11	8-9	NM_005188.3
<i>CBLC</i>	19	9, 11	NM_012116.4
<i>CDKN2A</i>	9	1-3	NM_000077.4
<i>CEBPA</i>	19	1	NM_004364.4
<i>CUX1</i>	7	1-24	NM_001202543
<i>DNMT3A</i>	2	2-23	NM_022552.4
<i>ETV6</i>	12	1-8	NM_001987
<i>EZH2</i>	7	2-20	NM_004456.4
<i>FBXW7</i>	4	9-11	NM_033632
<i>FLT3</i>	13	13-15, 20	NM_004119.2
<i>GATA2</i>	3	2-6	NM_032638.4
<i>GNAS</i>	20	8-10	NM_000516.4
<i>IDH1</i>	2	4	NM_005896.3
<i>IDH2</i>	15	4	NM_002168.3
<i>IKZF1</i>	7	2-8	NM_006060.6
<i>JAK2</i>	9	12,14	NM_004972
<i>JAK3</i>	19	13	NM_00215
<i>KDM6A</i>	X	1-29	NM_021140
<i>KIT</i>	4	2, 8-11, 13, 17	NM_000222.2
<i>KRAS</i>	12	2-3	NM_033360.3
<i>MPL</i>	1	10	NM_005373.2
<i>MYD88</i>	3	3-5	NM_002468
<i>NOTCH1</i>	9	26-28, 34	NM_017617
<i>NPM1</i>	5	11	NM_002520.6
<i>NRAS</i>	1	2-3	NM_002524.4
<i>PHF6</i>	X	2-10	NM_032458.2
<i>PTEN</i>	10	5, 7	NM_000314.8
<i>PTPN11</i>	12	3, 13	NM_002834.4
<i>RAD21</i>	8	2-14	NM_006265
<i>RUNX1</i>	21	2-9	NM_001754.4
<i>SF3B1</i>	2	13-16	NM_012433.3

<i>SMC1A</i>	X	2, 11, 16-17	NM_006306.4
<i>SMC3</i>	10	10,13, 19, 23, 25, 28	NM_005445.4
<i>SRSF2</i>	17	1	NM_003016
<i>STAG2</i>	X	3-35	NM_001042749
<i>TET2</i>	4	3-11	NM_001127208.2
<i>TP53</i>	17	2-11	NM_000546.5
<i>U2AF1</i>	21	2, 6	NM_006758.2
<i>WT1</i>	11	7, 9	NM_024426.4
<i>ZRSR2</i>	X	1-11	NM_005089.3

Supplementary Table S4: Multiplex cytokine assay

Cytokines LEGENDplex Human Inflammation Panel 1

IL-1 β

IFN- α 2

IFN- γ

TNF- α

MCP-1

IL-6

IL-8

IL-10

IL-12p70

IL-17A

IL-18

IL-23

IL-33

Supplementary Table S5: Principal component analysis

Cytokine name	Weight in the first principal component
IL-1 β [pg/ml]	0.059662112
IFN- α 2 [pg/ml]	0.005544896
IFN- γ [pg/ml]	0.003802583
TNF- α [pg/ml]	0.020426208
MCP-1 [pg/ml]	0.195629598
IL-6 [pg/ml]	0.024016677
IL-8 [pg/ml]	0.172703265
IL-10 [pg/ml]	0.014054166
IL-12p70 [pg/ml]	0.005796645
IL-17A [pg/ml]	0.003693312
IL-18 [pg/ml]	0.962251449
IL-23 [pg/ml]	0.005871354
IL-33 [pg/ml]	0.033117263

Supplementary Table S6: List of identified CHIP-associated variants

Gene	Chromosome	Exon	Locus	Variant (cDNA)	Variant (Protein)	VAF (%)	Variant Reads	Total Coverage
<i>ABL1</i>	9	E4	133738393	c.851_852delinsTT	p.Ser284Ile	2.0	70	3500
<i>ASXL1</i>	20	E13	31022288	c.1773C>A	p.Tyr591Ter	2.6	73	2808
<i>ASXL1</i>	20	E13	31022287	c.1772dupA	p.Tyr591Ter	13	429	3300
<i>ASXL1</i>	20	E13	31022900	c.2385_2394delCTGGGAAAGT	p.Trp796Metfs*19	9.9	463	4677
<i>ASXL1</i>	20	E13	31022883	c.2368_2371delGAGT	p.Glu790Leufs*27	37	2694	7281
<i>ASXL1</i>	20	E13	31023632	c.3117delA	p.Gln1039Hisfs*8	6.6	145	2197
<i>ATRX</i>	X	E21	76874432	c.5290T>A	p.Phe1764Ile	2.3	418	18174
<i>BCOR</i>	X	E10	39921499	c.4321C>G	p.Gln1441Glu	2.7	15	556
<i>BCOR</i>	X	E4	39932954	c.1645G>A	p.Gly549Ser	9.8	744	7592
<i>BCOR</i>	X	E9	39922093	c.4079A>G	p.Lys1360Arg	2.3	20	870
<i>BCORL1</i>	X	E3	129149742	c.2994dupC	p.Thr999Hisfs*7	7.8	177	2269
<i>BCORL1</i>	X	E3	129147736	c.988C>A	p.Leu330Ile	2	18	900
<i>BCORL1</i>	X	E3	129147709	c.961G>A	p.Val321Met	2.4	24	1000
<i>BCORL1</i>	X	E3	129147730	c.982T>A	p.Leu328Met	2.5	15	600
<i>BCORL1</i>	X	E3	129147217	c.469G>A	p.Ala157Thr	11	674	6127
<i>BCORL1</i>	X	E3	129149473	c.2725C>T	p.Arg909Trp	7.2	382	5306
<i>BCORL1</i>	X	E6	129159337	c.4061G>A	p.Arg1354Gln	41	1630	3976
<i>BCORL1</i>	X	E3	129149919	c.3171T>A	p.Asp1057Glu	2	50	2500
<i>BCORL1</i>	X	E3	129147916	c.1168T>C	p.Phe390Leu	2.1	48	2286
<i>BCORL1</i>	X	E3	129147695	c.947delT	p.Leu316Profs*102	2.2	16	727
<i>BRAF</i>	7	E15	140453154	c.1781A>G	p.Asp594Gly	12	1553	12942
<i>CBL</i>	11	E8	119148991	c.1211G>A	p.Cys404Tyr	16	1492	9325
<i>CEBPA</i>	19	E1	33792728	c.558_593delGCCGCGCCCTCGCACCC GCACCCGCACCCGCGCC	p.Pro187_Pro198del	9.8	17	173
<i>CEBPA</i>	19	E1	33792754	c.564_566dupGCC	p.Pro189dup	26	23	88
<i>CEBPA</i>	19	E1	33792727	c.556_594delCCGCGCCGCCCTCGC ACCCGCACCCGCACCCGCGCC	p.Pro186_Pro198del	2.1	17	810
<i>CEBPA</i>	19	E1	33792714	c.530_607delGCCTCTCCCTTACCAGCC GCCGCGCGCC CGCCGCCCTCGCACCCGCACCCGCAC	p.Gly177_Ala202del	17	16	94

				CCGCCGCCCGCGCACCTGGCCG				
<i>CEBPA</i>	19	E1	33792728	c.558_593delGCCGCCGCCCTCGCACCC GCACCCGCACCCGCCGCC	p.Pro187_Pro198del	4.8	16	333
<i>CUX1</i>	7	E6	101747699	c.523A>G	p.Lys175Glu	9.3	17	183
<i>DNMT3A</i>	2	E16	25466767	c.1936G>A	p.Gly646Arg	2.1	19	905
<i>DNMT3A</i>	2	E16	25466800	c.1903C>T	p.Arg635Trp	3	18	600
<i>DNMT3A</i>	2	E6	25497918	c.531G>C	p.Glu177Asp	2.3	16	696
<i>DNMT3A</i>	2	E20	25462006	c.2401A>G	p.Met801Val	9.8	307	3133
<i>DNMT3A</i>	2	E21	25459805	c.2478G>A	p.Lys826=	2.1	57	2714
<i>DNMT3A</i>	2	E16	25466816	c.1870_1886dupCCACCTGTCCCAGCTG A	p.Glu629Aspfs*28	4.8	46	958
<i>DNMT3A</i>	2	E17	25464493	c.2020A>G	p.Met674Val	7.9	16	203
<i>DNMT3A</i>	2	E13	25468187	c.1485_1489delCTCCT	p.Ile495Metfs*49	8.6	249	2895
<i>DNMT3A</i>	2	E23	25457242	c.2645G>A	p.Arg882His	9	329	3656
<i>DNMT3A</i>	2	E15	25467205	c.1670G>A	p.Cys557Tyr	16	519	3244
<i>DNMT3A</i>	2	E8	25470557	c.917G>A	p.Trp306Ter	4.9	490	10000
<i>DNMT3A</i>	2	E19	25463289	c.2204A>T	p.Tyr735Phe	17	705	4147
<i>DNMT3A</i>	2	E23	25457288	c.2599delG	p.Val867Tyrfs*14	4.5	106	2356
<i>DNMT3A</i>	2	E16	25466799	c.1904G>A	p.Arg635Gln	14	133	950
<i>DNMT3A</i>	2	E18	25463562	c.2120G>A	p.Gly707Asp	2.6	78	3000
<i>DNMT3A</i>	2	E19	25463287	c.2206C>T	p.Arg736Cys	2.5	98	3920
<i>DNMT3A</i>	2	E16	25466770	c.1933A>G	p.Thr645Ala	4.4	47	1068
<i>DNMT3A</i>	2	E18	25463599	c.2083A>T	p.Ile695Phe	5	163	3260
<i>DNMT3A</i>	2	E19	25463181	c.2312G>A	p.Arg771Gln	19	332	1747
<i>DNMT3A</i>	2	E23	25457243	c.2644C>T	p.Arg882Cys	4.2	114	2714
<i>DNMT3A</i>	2	E21	25459806	c.2477A>G	p.Lys826Arg	3.6	111	3083
<i>DNMT3A</i>	2	E23	25457242	c.2645G>A	p.Arg882His	7.5	244	3253
<i>DNMT3A</i>	2	E9	25469976	c.1066C>T	p.Gln356Ter	3	30	1000
<i>DNMT3A</i>	2	E23	25457250	c.2637C>G	p.Asn879Lys	2.6	88	3385
<i>DNMT3A</i>	2	E13	25468141	c.1522_1535delCTCTTCGTTGGAGG	p.Leu508Asnfs*33	7.3	218	2986
<i>DNMT3A</i>	2	E15	25467119	c.1756T>A	p.Cys586Ser	2.1	56	2667
<i>DNMT3A</i>	2	E10	25469642	c.1126G>C	p.Ala376Pro	5	37	740

<i>DNMT3A</i>	2	E18	25463540	c.2140_2141dupTC	p.Ile715Profs*65	3	100	3333
<i>DNMT3A</i>	2	E8	25470497	c.977G>A	p.Arg326His	5.4	158	2926
<i>DNMT3A</i>	2	E19	25463184	c.2309C>T	p.Ser770Leu	7.4	259	3500
<i>DNMT3A</i>	2	E15	25467033	c.1841_1842delAC	p.Asp614Alafs*4	7.4	205	2770
<i>DNMT3A</i>	2	E19	25463289	c.2204A>G	p.Tyr735Cys	20	1209	6045
<i>DNMT3A</i>	2	E23	25457168	c.2719G>T	p.Glu907Ter	14	203	1450
<i>DNMT3A</i>	2	E8	25470498	c.976C>A	p.Arg326Ser	3.3	83	2515
<i>DNMT3A</i>	2	E23	25457243	c.2644C>T	p.Arg882Cys	2.2	85	3864
<i>DNMT3A</i>	2	E6	25497897	c.500_552delGGGGCCGGCTGCGGGGT GGCTTG GGCTGGGAGTCCAGCCTCCGTCAGCG GCCC	p.Arg167Hisfs*31	2.4	26	1083
<i>DNMT3A</i>	2	E10	25469605	c.1163delA	p.His388Profs*19	26	492	1892
<i>DNMT3A</i>	2	E23	25457243	c.2644C>T	p.Arg882Cys	28	1263	4511
<i>DNMT3A</i>	2	E11	25469044	c.1414delG	p.Asp472Metfs*179	3.9	114	2923
<i>DNMT3A</i>	2	E19	25463277	c.2216A>C	p.His739Pro	7.7	512	6649
<i>DNMT3A</i>	2	E21	25459809	c.2470_2473dupATAG	p.Ala825Aspfs*31	5	171	3420
<i>DNMT3A</i>	2	E16	25466800	c.1903C>T	p.Arg635Trp	5.4	42	778
<i>DNMT3A</i>	2	E9	25469968	c.1074delG	p.Tyr359Thrfs*48	8.9	150	1685
<i>DNMT3A</i>	2	E19	25463186	c.2307C>G	p.Ile769Met	9.3	386	4151
<i>DNMT3A</i>	2	E20	25462030	c.2377T>G	p.Tyr793Asp	2.7	142	5259
<i>DNMT3A</i>	2	E19	25463181	c.2312G>A	p.Arg771Gln	35	1191	3403
<i>DNMT3A</i>	2	E17	25464568	c.1945G>C	p.Val649Leu	17	31	182
<i>DNMT3A</i>	2	E9	25470011	c.1031T>C	p.Leu344Pro	3.1	65	2097
<i>DNMT3A</i>	2	E14	25467496	c.1580A>C	p.Gln527Pro	2.3	110	4783
<i>EZH2</i>	7	E2	148544341	c.50A>G	p.Lys17Arg	3.9	20	513
<i>GNAS</i>	20	E8	57484421	c.602G>A	p.Arg201His	13	49	377
<i>IDH2</i>	15	E4	90631934	c.419G>A	p.Arg140Gln	12	996	8300
<i>KDM6A</i>	X	E24	44945224	c.3548A>G	p.Lys1183Arg	2.3	26	1130
<i>KDM6A</i>	X	E17	44929161	c.2261T>C	p.Met754Thr	2	19	950
<i>KDM6A</i>	X	E1	44732865	c.68A>G	p.Lys23Arg	4.6	20	435
<i>KRAS</i>	12	E2	25398284	c.35G>T	p.Gly12Val	41	4340	10585

<i>MYD88</i>	3	E3	38182056	c.680A>G	p.Lys227Arg	2.2	18	818
<i>NOTCH1</i>	9	E26	139399222	c.4921C>T	p.Pro1641Ser	3.3	17	515
<i>NOTCH1</i>	9	E34	139390795	c.7396A>G	p.Thr2466Ala	3.1	20	645
<i>PHF6</i>	X	E2	133511703	c.56T>G	p.Phe19Cys	6.5	16	246
<i>PHF6</i>	X	E10	133559253	c.991G>A	p.Gly331Arg	4.1	151	3683
<i>PHF6</i>	X	E7	133547860	c.593G>A	p.Arg198Lys	2.6	108	4154
<i>RAD21</i>	8	E7	117868887	c.812C>G	p.Ser271Ter	2.1	119	5667
<i>SMC1A</i>	X	E17	53423482	c.2618T>C	p.Leu873Pro	2.2	21	955
<i>SMC3</i>	10	E28	112363035	c.3569A>G	p.Lys1190Arg	2.3	26	1130
<i>SRSF2</i>	17	E1	74732959	c.284C>A	p.Pro95His	11	136	1236
<i>SRSF2</i>	17	E1	74732959	c.284C>T	p.Pro95Leu	3.2	18	563
<i>STAG2</i>	X	E28	123215311	c.2857C>G	p.Arg953Gly	4.3	149	3465
<i>TET2</i>	4	E10	106193779	c.4241A>G	p.Gln1414Arg	5.5	370	6727
<i>TET2</i>	4	E11	106196930	c.5263G>T	p.Glu1755Ter	8.6	1172	13628
<i>TET2</i>	4	E8	106182971	c.4010dupA	p.Tyr1337Ter	5.3	203	3830
<i>TET2</i>	4	E3	106155427	c.328A>T	p.Lys110Ter	8.2	839	10232
<i>TET2</i>	4	E9	106190818	c.4096C>T	p.Arg1366Cys	12	398	3317
<i>TET2</i>	4	E3	106155675	c.576C>G	p.Tyr192Ter	11	1097	9973
<i>TET2</i>	4	E3	106158506	c.3407dupT	p.Glu1137Argfs*5	2.3	141	6130
<i>TET2</i>	4	E11	106196611	c.4944delC	p.Tyr1649Ilefs*46	16	2258	14113
<i>TET2</i>	4	E3	106156723	c.1624A>T	p.Lys542Ter	2.4	61	2542
<i>TET2</i>	4	E9	106190826	c.4104_4110delCTCAGGG	p.Phe1368Leufs*78	4.1	202	4927
<i>TET2</i>	4	E9	106190849	c.4127A>G	p.Asp1376Gly	15	705	4700
<i>TET2</i>	4	E7	106180784	c.3812dupG	p.Cys1271Trpfs*29	4.6	268	5826
<i>TET2</i>	4	E6	106164916	c.3784C>T	p.Arg1262Trp	2.3	83	3609
<i>TET2</i>	4	E11	106196213	c.4546C>T	p.Arg1516Ter	2.9	279	9621
<i>TET2</i>	4	E3	106155291	c.192_193insG	p.Cys65Valfs*8	3.9	160	4103
<i>TET2</i>	4	E9	106190819	c.4097G>A	p.Arg1366His	5.3	254	4792
<i>TET2</i>	4	E3	106157953	c.2854delC	p.Leu952Ter	3.2	447	13969
<i>TET2</i>	4	E3	106158372	c.3273delA	p.Pro1092Glnfs*14	5.4	531	9833
<i>TP53</i>	17	E5	7578446	c.484A>T	p.Ile162Phe	4	81	2025

<i>TP53</i>	17	E7	7577538	c.743G>A	p.Arg248Gln	3.8	489	12868
<i>TP53</i>	17	E4	7579448	c.213_239delCCCCGTGGCCCCTGCACC AGCAGCTCC	p.Pro72_Pro80del	2.3	38	1652
<i>TP53</i>	17	E4	7579394	c.293C>A	p.Pro98His	4	31	775
<i>TP53</i>	17	E4	7579350	c.337T>A	p.Phe113Ile	24	329	1371
<i>TP53</i>	17	E10	7574030	c.997C>G	p.Arg333Gly	3.8	15	395
<i>TP53</i>	17	E6	7578265	c.584T>C	p.Ile195Thr	2.3	57	2478
<i>TP53</i>	17	E5	7578395	c.535C>G	p.His179Asp	2.1	33	1571
<i>U2AF1</i>	21	E2	44524456	c.101C>T	p.Ser34Phe	4.8	995	20729
<i>ZRSR2</i>	X	E11	15841177	c.1261C>T	p.Arg421Ter	4.4	201	4568
<i>ZRSR2</i>	X	E11	15841259	c.1332_1343dupGAGCCGGAGCCG	p.Ser445_Arg448dup	88	382	434
<i>ZRSR2</i>	X	E4	15821882	c.275A>G	p.Lys92Arg	2.3	23	1000
<i>ZRSR2</i>	X	E4	15821888	c.281A>G	p.Glu94Gly	2.1	20	952

Data on intra- and inter-assay variation

Intra-assay variation (measured in duplicates)

Analyte	Sample	Mean (pg/ml)	SD	%CV
hIL-1 β	Sample 1 (Patient A)	7.74	1.25	4.29
	Sample 2 (Patient B)	2.89	0.00	0.00
	Sample 3 (Patient C)	567.79	32.33	13.45
hIFN- α 2	Sample 1	9.18	0.26	1.99
	Sample 2	3.64	0.30	2.77
	Sample 3	12.74	0.35	2.48
hIFN- γ	Sample 1	7.84	0.00	0.00
	Sample 2	7.28	0.56	6.73
	Sample 3	8.40	0.56	6.15
hTNF- α	Sample 1	11.69	2.43	11.79
	Sample 2	10.47	1.22	6.15
	Sample 3	3.33	0.00	0.00
hMCP-1	Sample 1	147.16	9.30	13.00
	Sample 2	468.73	20.24	13.52
	Sample 3	80.22	5.33	10.88
hIL-6	Sample 1	17.26	1.12	6.73
	Sample 2	10.03	1.31	9.43
	Sample 3	7.33	0.00	0.00
hIL-8	Sample 1	12.34	3.64	12.86
	Sample 2	11.61	2.91	10.48
	Sample 3	13.06	0.00	0.00
hIL-10	Sample 1	11.47	2.14	15.29
	Sample 2	2.55	0.96	14.14
	Sample 3	4.92	0.14	1.43
hIL-12p70	Sample 1	6.64	1.00	12.86
	Sample 2	1.54	0.10	10.88
	Sample 3	2.25	0.14	3.01
hIL-17A	Sample 1	1.81	0.30	8.84
	Sample 2	0.69	0.25	11.79
	Sample 3	0.58	0.03	1.52
hIL-18	Sample 1	411.30	19.91	8.77
	Sample 2	381.33	13.53	6.36
	Sample 3	226.62	27.63	19.64
hIL-23	Sample 1	9.03	0.81	4.56
	Sample 2	17.36	0.39	1.70
	Sample 3	3.00	0.40	3.01
hIL-33	Sample 1	55.17	1.67	2.24
	Sample 2	29.52	0.00	0.00
	Sample 3	79.38	6.26	7.25

Overall intra-assay variation depicted as median of %CV of each analyte

Analyte	%CV
hIL-1 β	7.44
hIFN- α 2	4.04
hIFN- γ	7.44
hTNF- α	8.32
hMCP-1	13.31
hIL-6	8.32
hIL-8	11.7
hIL-10	7.86
hIL-12p70	6.15
hIL-17A	8.84
hIL-18	11.9
hIL-23	3.82
hIL-33	5.62

Inter-assay variation (measured in triplicates)

Analyte	Sample	Mean (pg/ml)	SD	%CV
hIL-1 β	Sample 1 (Patient D)	2.89	0.73	25.29
	Sample 2 (Patient E)	14.59	1.93	13.22
	Sample 3 (Patient F)	19.04	3.09	16.25
hIFN- α 2	Sample 1	0.59	0.11	18.62
	Sample 2	0.45	0.03	6.29
	Sample 3	0.63	0.23	36.42
hIFN- γ	Sample 1	2.93	1.16	39.78
	Sample 2	3.88	0.18	4.55
	Sample 3	3.26	0.70	21.51
hTNF- α	Sample 1	1.51	0.11	7.25
	Sample 2	1.51	0.11	7.25
	Sample 3	2.07	0.89	43.10
hMCP-1	Sample 1	165.00	33.07	20.04
	Sample 2	251.66	60.74	24.14
	Sample 3	80.95	10.79	13.33
hIL-6	Sample 1	5.10	0.58	11.29
	Sample 2	4.15	1.14	27.51
	Sample 3	10.42	1.43	13.75
hIL-8	Sample 1	3.37	0.51	15.01
	Sample 2	3.37	0.51	15.01
	Sample 3	4.44	1.00	22.43

hIL-10	Sample 1	2.38	0.62	26.17
	Sample 2	1.22	0.12	9.73
	Sample 3	1.62	0.18	11.42
hIL-12p70	Sample 1	0.84	0.15	18.14
	Sample 2	0.95	0.11	11.97
	Sample 3	1.94	0.54	27.66
hIL-17A	Sample 1	0.48	0.03	5.32
	Sample 2	0.48	0.03	5.32
	Sample 3	0.62	0.22	35.40
hIL-18	Sample 1	34.73	1.12	3.21
	Sample 2	36.98	1.14	3.08
	Sample 3	89.12	6.87	7.71
hIL-23	Sample 1	1.09	0.14	13.12
	Sample 2	1.09	0.14	13.12
	Sample 3	1.19	0.00	0.00
hIL-33	Sample 1	3.93	0.89	22.75
	Sample 2	6.48	0.57	8.73
	Sample 3	2.52	0.35	14.03

Inter-assay variation (across 3 samples) depicted as median of %CV of each analyte

Analyte	%CV
hIL-1 β	16.25
hIFN- α 2	18.62
hIFN- γ	21.51
hTNF- α	7.25
hMCP-1	20.04
hIL-6	13.75
hIL-8	15.01
hIL-10	11.42
hIL-12p70	18.14
hIL-17A	5.32
hIL-18	3.21
hIL-23	13.12
hIL-33	14.03

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3, 4
Objectives	3	State specific objectives, including any prespecified hypotheses	4, 5,6
Methods			
Study design	4	Present key elements of study design early in the paper	5, 6, 8, 9, 10
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5,6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5, Supplement page no. 2, 3
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5, 6, 7, 8, 9, 10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6,7 ,8
Bias	9	Describe any efforts to address potential sources of bias	9, 10
Study size	10	Explain how the study size was arrived at	5, 6, Supplement

			page no. 2, 3
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8, 9, 10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8, 9, 10
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	5, 9, Supplement page no. 2, 3
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	5, 9
		(e) Describe any sensitivity analyses	NA

Continued on next page

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Supplement page no. 3
		(b) Give reasons for non-participation at each stage	Supplement page no. 3
		(c) Consider use of a flow diagram	Supplement page no. 3
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10, 27, 28
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	5
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	6, Supplement page no. 4
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	10
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	NA
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10, 11, 12
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	11
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11
Discussion			
Key results	18	Summarise key results with reference to study objectives	16
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15,16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12, 13, 14, 15
Generalisability	21	Discuss the generalisability (external validity) of the study results	12, 13, 15

Other information

Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

16, 17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.